Prof. Dr. Alexandru Trestioreanu Oncologic Institute
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gales, Laurentia Nicoleta
PEACE6-Unfit, NCT04916613 / 2020-003663-26: ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Recruiting
3
300
Europe
Darolutamide 300 mg, Nubeqa®, Placebo, Androgen deprivation therapy, ADT
UNICANCER, Bayer
Prostate Cancer Metastatic
03/28
09/37
HexAgon-HN, NCT06295731: INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Recruiting
2/3
410
Europe, US, RoW
INBRX-106, Hexavalent OX40 agonist antibody, Pembrolizumab, Keytruda
Inhibrx Biosciences, Inc
Head and Neck Squamous Cell Carcinoma (HNSCC)
05/29
05/29
GALAXIES H&N-202, NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck-

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
NCT06299839: PAS-004 in Patients With Advanced Solid Tumors

Recruiting
1
48
Europe, US
PAS-004 Capsules, PAS-004 Tablets
Pasithea Therapeutics Corp.
RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
12/25
02/27
FS222-19101, NCT04740424: FS222 First in Human Study in Patients With Advanced Malignancies

Recruiting
1
260
Europe, RoW
FS222
invoX Pharma Limited
Advanced Cancer, Metastatic Cancer
10/27
10/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gales, Laurentia Nicoleta
PEACE6-Unfit, NCT04916613 / 2020-003663-26: ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Recruiting
3
300
Europe
Darolutamide 300 mg, Nubeqa®, Placebo, Androgen deprivation therapy, ADT
UNICANCER, Bayer
Prostate Cancer Metastatic
03/28
09/37
HexAgon-HN, NCT06295731: INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Recruiting
2/3
410
Europe, US, RoW
INBRX-106, Hexavalent OX40 agonist antibody, Pembrolizumab, Keytruda
Inhibrx Biosciences, Inc
Head and Neck Squamous Cell Carcinoma (HNSCC)
05/29
05/29
GALAXIES H&N-202, NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck-

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
NCT06299839: PAS-004 in Patients With Advanced Solid Tumors

Recruiting
1
48
Europe, US
PAS-004 Capsules, PAS-004 Tablets
Pasithea Therapeutics Corp.
RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
12/25
02/27
FS222-19101, NCT04740424: FS222 First in Human Study in Patients With Advanced Malignancies

Recruiting
1
260
Europe, RoW
FS222
invoX Pharma Limited
Advanced Cancer, Metastatic Cancer
10/27
10/27

Download Options